Chronic low-grade inflammation is the core issue in the functional medicine dimension of immune-inflammatory imbalance and serves as a common pathological basis for cardiovascular disease, metabolic syndrome, autoimmune disorders, and neurodegenerative diseases. The NF-κB (nuclear factor kappa B) pathway acts as the central transcriptional switch for inflammatory responses, regulating the expression of pro-inflammatory factors such as TNF-α, IL-6, and COX-2.
Curcumin, a polyphenol extracted from turmeric rhizomes, is one of the most extensively studied natural anti-inflammatory molecules. Extensive in vitro and animal studies show that curcumin inhibits NF-κB activation through multiple pathways: directly inhibiting IKKβ kinase (preventing IκB degradation), blocking NF-κB nuclear translocation, and downregulating COX-2 and 5-LOX expression.
However, curcumin's core challenge is its extremely low bioavailability: after oral administration, it undergoes rapid metabolism in the gut (glucuronidation and sulfation), leaving almost no detectable parent compound in the blood. This severely limits its clinical value.
Breakthroughs in formulation technology have changed this landscape. Phospholipid complex technology (curcumin combined with soy lecithin) increases bioavailability by approximately 29 times; nano-micelle technology (e.g., Novasome®) forms water-soluble nanoparticles, boosting bioavailability up to 2000 times. Pairing curcumin with piperine (a black pepper extract that inhibits liver and intestinal metabolic enzymes) further extends its residence time in the body.
In functional medicine product development, high-bioavailability curcumin is the core ingredient of the Immune Resilience Series. Dynas Group (Hong Kong) offers custom curcumin solutions via phospholipid complex and nano-micelle technologies, available in softgels and tablets. We provide brands with clinically supported anti-inflammatory solutions.
